Harvard Bioscience Inc (HBIO)

Harvard Bioscience, Inc. is a common stock listed on NASDAQ that represents equity in a life sciences tools and services company. The company develops, manufactures, and sells technologies, products, and related services for laboratory and research applications in the United States, Germany, and other international markets. Its portfolio includes cellular and molecular technology products such as infusion pumps, electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and equipment used in molecular testing and research. Harvard Bioscience also provides preclinical and physiological research tools, including telemetry systems, behavioral products, isolated organ and surgical products, respiratory testing solutions, inhalation and exposure systems, and data acquisition and analysis platforms. Its products are marketed to pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, contract research organizations, and academic labs through sales teams, websites, and distributors. The company sells under brands including Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab. Founded in 1901, Harvard Bioscience is based in Holliston, Massachusetts.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-HBIO
$9.01
13.3% Upside
Fair
$7.50
-5.7% Downside
Fair
Fair
0.0%
November 10, 2026
4.9x
0.4x
36.236 M
74.212 M
54.7%
78.1%
-2.8
10.7%
Valuation • Fair Value

Harvard Bioscience Inc (NASDAQ-HBIO) Fair Value by Valuation Model

Review the available estimates for Harvard Bioscience Inc (NASDAQ-HBIO), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$9.01

Estimated upside of 13.3% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$8.66

Discounted cash flow valuation reference.

EPV Fair Value

$6.62

Earnings power value estimate.

Comps Fair Value

$9.75

Comparable-company valuation reference.

Analyst Price Target

$7.50

Analysts imply downside of 5.7%.

How to read these valuation models

Use the 6 available valuation references for Harvard Bioscience Inc (NASDAQ-HBIO) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Harvard Bioscience Inc (NASDAQ-HBIO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

87.808 M

Current operating scale indicator.

Revenue Forecast

89.8 M

Forward revenue estimate.

EBITDA

7.37 M

Current operating profitability reference.

EBITDA Forecast

8.7 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Harvard Bioscience Inc (NASDAQ-HBIO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Harvard Bioscience Inc (NASDAQ-HBIO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.93

No elevated caution signal from this screen.

Altman Z-Score

-2.8

Lower score that deserves closer risk review.

FCF / Net Income

10.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Harvard Bioscience Inc (NASDAQ-HBIO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Harvard Bioscience Inc (NASDAQ-HBIO)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 10, 2026

Days to Earnings

53

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Harvard Bioscience Inc (NASDAQ-HBIO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Harvard Bioscience Inc (NASDAQ-HBIO) Stock Forecast & Technical Outlook

Review Harvard Bioscience Inc (NASDAQ-HBIO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Harvard Bioscience Inc (NASDAQ-HBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Harvard Bioscience Inc (NASDAQ-HBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Harvard Bioscience Inc (NASDAQ-HBIO) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Harvard Bioscience Inc (NASDAQ-HBIO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Harvard Bioscience Inc (NASDAQ-HBIO) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Harvard Bioscience Inc (NASDAQ-HBIO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Harvard Bioscience Inc (NASDAQ-HBIO) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ Fast Investor Answers

Harvard Bioscience Inc (NASDAQ-HBIO) Stock FAQ

Data-supported answers about Harvard Bioscience Inc (NASDAQ-HBIO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$9.01
Estimated upside 13.3%
Valuation Rating
Undervalued
Estimated upside of 13.3%
Analyst Target
$7.50
Implied downside 5.7%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Harvard Bioscience Inc (NASDAQ-HBIO) is $9.01. This implies an estimated upside of 13.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 13.3% versus the current market price.

The available analyst price target for Harvard Bioscience Inc (NASDAQ-HBIO) is $7.50. The analyst target implies estimated downside of 5.7%.

The current financial health read for Harvard Bioscience Inc (NASDAQ-HBIO) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Harvard Bioscience Inc (NASDAQ-HBIO) is November 10, 2026.

The latest available data indicates no current dividend yield for Harvard Bioscience Inc (NASDAQ-HBIO).

The current market capitalization listed for Harvard Bioscience Inc is 36.236 M.

The current enterprise value listed for Harvard Bioscience Inc is 74.212 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Harvard Bioscience Inc is NASDAQ-HBIO, and the stock is listed on NASDAQ.

Harvard Bioscience Inc (NASDAQ-HBIO) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Harvard Bioscience Inc is 54.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Harvard Bioscience Inc is 78.1%. Free float helps investors understand how much of the share base is available for public trading.